Cardiovascular risk and who gets a statin
- Follow-up and treatment
Statins are among the best medicines against heart attack and stroke. The art is knowing who needs one, how strong, and how low LDL should go.
What it is
Statins block HMG-CoA reductase, the liver's cholesterol factory; the liver answers by making more LDL receptors and pulling LDL out of the blood. Each fall in LDL cholesterol reduces cardiovascular events in proportion, whatever the starting value. Who gets a statin depends on the absolute risk of an event: people with atherosclerotic disease, LDL of 190 mg/dL or more, diabetes in mid-life or chronic kidney disease are treated directly; everyone else is treated according to a calculated 10-year risk. Intensity and LDL targets rise with risk.
What to know
- Risk tools combine age, sex, smoking, blood pressure, cholesterol and diabetes: Framingham, the US pooled cohort or PREVENT equations, European SCORE2 and the WHO regional charts.
- Imported risk tools miscalibrate in other populations; Colombian guidance has used a Framingham score adjusted to the Colombian population.
- Statin without a calculator: established atherosclerotic disease, LDL of 190 mg/dL or more, diabetes in adults aged 40–75, and moderate to severe chronic kidney disease.
- Intensity in principle: high intensity lowers LDL by 50% or more, moderate by 30–49%; higher doses of atorvastatin or rosuvastatin reach high intensity.
- European targets by risk: very high under 55 mg/dL (1.4 mmol/L) with a 50% fall, high under 70 mg/dL, moderate under 100 mg/dL, low under 116 mg/dL.
- Risk enhancers that favour treatment: family history of premature disease, high Lp(a), metabolic syndrome, chronic inflammatory disease, HIV, early menopause, pre-eclampsia.
- A coronary artery calcium score can reclassify intermediate risk: a score of zero can justify waiting, except in smokers, diabetes and familial hypercholesterolaemia.
- Add-ons when the target is not met: ezetimibe first, then a PCSK9 inhibitor or inclisiran; bempedoic acid when statins are not tolerated; bile acid sequestrants rarely.
- For residual high triglycerides in high-risk patients on a statin, icosapent ethyl reduced events; fibrates did not, and are kept mainly to prevent pancreatitis.
Who gets what, in principle (European-style targets)
| Risk category | Examples | Statin | LDL target |
|---|---|---|---|
| Very high | Coronary, cerebrovascular or peripheral arterial disease; diabetes with organ damage; severe kidney disease | High intensity, plus add-ons as needed | Under 55 mg/dL and a 50% fall |
| High | LDL 190 mg/dL or more or familial hypercholesterolaemia; long-standing diabetes; moderate kidney disease; high calculated risk | High intensity | Under 70 mg/dL and a 50% fall |
| Moderate | Intermediate calculated risk; young people with short-duration diabetes | Moderate intensity if risk or enhancers justify it | Under 100 mg/dL |
| Low | Low calculated risk | Lifestyle; drug rarely | Under 116 mg/dL |
In the clinic
- Most muscle aches on statins are not caused by the statin: in blinded trials the same symptoms appeared on placebo, and most patients tolerate a rechallenge.
- True statin myopathy is uncommon and rhabdomyolysis rare; risk rises with hypothyroidism, kidney disease, old age, and interacting drugs (gemfibrozil, some macrolides and azoles with simvastatin).
- Statins slightly raise the chance of diabetes in people already close to it; the cardiovascular benefit is much larger.
- Stable fatty liver and mildly raised liver enzymes are not reasons to withhold a statin; routine monitoring of muscle enzymes is not needed.
- Statins are stopped before conception and in pregnancy.
Next step / Initial management
- Baseline lipid profile, ALT, glucose or HbA1c, creatinine and TSH; measure CK only if muscle symptoms appear.
- Calculate 10-year risk (skip it in established disease, familial hypercholesterolaemia and LDL of 190 mg/dL or more) and agree the target with the patient.
- Start a statin of the intensity the risk demands; check the lipid profile 4–12 weeks later, then yearly; add ezetimibe if the target is not met.
- Refer to a lipid clinic or endocrinology for suspected familial hypercholesterolaemia, targets not met on statin plus ezetimibe, true intolerance to several statins, or very high Lp(a).
Common traps
- Muscle pain on a statin proves statin intolerance: blinded trials show most symptoms also occur on placebo, so rechallenge with another statin or lower intensity before labelling.
- The LDL is «normal» so no statin is needed: decisions follow absolute risk, and a patient with a heart attack benefits from lowering any LDL further.
- Risk calculators work in every patient: they underestimate risk in familial hypercholesterolaemia and are not used once atherosclerotic disease is present.
- Fibrates are the next step when the statin is not enough: on top of a statin they did not reduce cardiovascular events; ezetimibe and PCSK9-targeted drugs did.
- Statins damage the liver, so check enzymes often: serious liver injury is very rare and stable fatty liver may even benefit, so one baseline ALT is enough.
Test yourself
Think of the answer, then tap the question to see it.
A 62-year-old had a heart attack; his LDL is 98 mg/dL on moderate-intensity statin. What do you do?
Switch to a high-intensity statin and aim for LDL under 55 mg/dL with a 50% fall; add ezetimibe if the target is still not met.
A woman stopped her statin because of leg aches; CK is normal. What is the best next step?
Rechallenge after a washout with another statin or a lower intensity: most aches are not caused by the statin and most patients then tolerate one.
A 50-year-old with LDL 200 mg/dL has a low Framingham risk. Does he need a statin?
Yes: LDL of 190 mg/dL or more means probable familial hypercholesterolaemia, and risk calculators underestimate risk in it.
Why are add-ons such as ezetimibe preferred over fibrates in a statin-treated patient above target?
Because the benefit follows LDL lowering: ezetimibe and PCSK9-targeted drugs lowered LDL and events, while fibrates on top of statins did not cut events.
Elsewhere in DurgiPedia
- Cholesterol synthesis (mevalonate pathway)
- LDL receptor
- PCSK9
- Cholesterol
- Atherosclerosis: risk factors
- Consequences of atherosclerosis
Connections
Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.
Sources: Statin Medications (StatPearls (NCBI Bookshelf), 2024); Hyperlipidemia (StatPearls (NCBI Bookshelf), 2023); Hypercholesterolemia (StatPearls (NCBI Bookshelf), 2023); PCSK9 Inhibitors (StatPearls (NCBI Bookshelf), 2024); Lipoprotein A (StatPearls (NCBI Bookshelf), 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
